Browse studies
Find your next paid study
4 recruiting studies matching your filters
Observational
Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention
This study will evaluate strategies to improve physical function and promote exercise and physical activity in adolescents and young adults (AYAs) with sarcoma…
SarcomaBone SarcomaSoft Tissue Sarcoma (STS)
Estimated
~$10 – $7,500
Dana-Farber Cancer InstituteNCT07662239
Phase 1
EPITOME-1015-I: a Phase I Study to Investigate the Safety, Tolerability and Preliminary Efficacy of a Third Generation TCR-T Therapy, MDG1015, in Epithelial Ovarian Carcinoma, Gastroesophageal (Junction) Adenocarcinoma, Myxoid (Round Cell) Liposarcoma And/or Synovial Sarcoma Subjects with Advanced Disease Expressing NY-ESO-1 And/or LAGE-1a
MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP). The stu…
Epithelial Ovarian CancerGastro-esophageal Junction CancerSoft Tissue Sarcoma (STS)+2 more
Estimated
~$10 – $8,750
Medigene AGNCT06748872
Phase 1
5-AminoLevulinic Acid Aided Resection Margins in Sarcoma (5-ALARMS)
The goal of this study is to learn if the intervention using a fluorescent agent 5-Aminolevulinic acid (5-ALA) to aid in the surgical approach to visualize the…
Soft Tissue Sarcoma (STS)
Estimated
~$10 – $6,250
University of Colorado, DenverNCT07038278
Phase 1
An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination wi…
Advanced Solid TumorMetastatic Solid TumorSoft Tissue Sarcoma (STS)+6 more
Estimated
~$10 – $8,750
GI Innovation, Inc.NCT05824975